Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emiltatug Ledadotin - Mersana Therapeutics

Next Previous
Drug Profile

Emiltatug Ledadotin - Mersana Therapeutics

Alternative Names: B7-H4 ADC - Mersana Therapeutics; B7-H4 targeting antibody drug conjugate - Mersana Therapeutics; Emi-Le; XMT-1660

Latest Information Update: 26 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mersana Therapeutics
  • Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Adenoid cystic carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer

Most Recent Events

  • 26 Sep 2025 Phase I development for Endometrial cancer, Fallopian tube cancer, Ovarian cancer and Triple-negative-breast-cancer, in USA is still ongoing (IV) (NCT05377996)
  • 02 Jun 2025 Updated efficacy data from a phase I trial in Triple negative breast cancer released by Mersana Therapeutics
  • 10 Jan 2025 XMT 1660 receives Fast Track designation for Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top